Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.50 |
| ▸ | ESR1 | P03372 | 6/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | TNKS | O95271 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL822675 | 0.85 | L3MBTL1 (0.56) | NAMPTHPGDHTR2AHTR2CHTR2B | |
| SCHEMBL20380039 | 0.83 | NAMPT (0.47) | NAMPTHPGDHTR2AHTR2CHTR2B | |
| SCHEMBL29941716 | 0.83 | NAMPT (0.47) | NAMPTHPGDHTR2AHTR2CHTR2B | |
| Acetic Acid SCHEMBL15622681 | 0.81 | KMT2A (0.57) | NAMPTHPGDL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL1376771 | 0.80 | HPGD (0.71) | HPGDL3MBTL1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL4030264 | 0.78 | NAMPT (0.53) | NAMPTESR1L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4026003 | 0.78 | ESR1 (0.54) | NAMPTESR1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL4027878 | 0.78 | ESR1 (0.63) | ESR1HPGDKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL4034165 | 0.77 | ESR1 (0.65) | ESR1HPGDKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL9468801 | 0.77 | KDM4E (0.48) | NAMPTHPGDHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542976-B1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7241791-B2 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2007-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | INSR, TNNI3, INSRR | NAMPT 4390/4885ESR1 1028/4885HPGD 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.